FINHUB Insights

Language: EN
Sign in Sign up

Bristol Myers Squibb Q1 FY25: where the revenue came from and where it went

The whole income statement of Bristol Myers Squibb for this quarter, as one diagram: what earned the revenue, and what it went on.

Period
Jan 1 – Mar 31, 2025
Reported
Apr 24, 2025 10-Q accession 0000014272-25-000091

Revenue$11.20B −6% year over year
Gross profit$8.17B 73% margin
Operating profit−$0.51B −5% margin
Net profit$2.46B 22% margin

Net profit is larger than what operations earned, because the statement adds $3.48B below it, under Other income, net.

100% free

It's free. All of it.

A free account opens every diagram. We send one link to confirm your address, and that is the whole of it.

Continue with Google Create a free account

Already have an account? Sign in

The numbers

All figures in billions of U.S. dollars, for Q1 FY25 (period ends Mar 31, 2025).
ItemValueShare of revenueYear over year
Revenue 11.20 100% −6%
Eliquis 3.57 32%
Opdivo 2.27 20%
Other revenue 1.96 17%
Revlimid 0.94 8%
Orencia 0.77 7%
Pomalyst/Imnovid 0.66 6%
Yervoy 0.62 6%
Reblozyl 0.48 4%
Other and unallocated −0.05 0%
Cost of revenue−3.0327%
Gross profit8.1773% margin−2pp
R&D−2.2620%−3pp
SG&A−1.5814%−6pp
Other−4.8443%+0pp
Operating profit−0.51−5% margin+0pp
Other income, net3.48
Tax−0.51
Net profit2.46 22% margin+122pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Filing on EDGAR More quarters of BMY

220 of 418 companies, most recently reported first